Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen DNA vaccine GNOS-PV01
- Development stage
- Phase 1
- Lead developer
- Geneos Therapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A personalized cancer vaccine consisting of patient-specific neoantigen-coding DNA plasmids. These plasmids are designed to encode immunogenic sequences unique to the patient's tumor. The resulting product is intended to stimulate the immune system by presenting these tumor-specific antigens and thereby induce a targeted anti-tumor immune response. The primary mechanism is immunomodulation through activation of T cells against tumor-specific neoantigens. Developed for use in cancers such as glioblastoma and hepatocellular carcinoma, this therapy is being developed by Geneos Therapeutics (a spinout of Inovio Pharmaceuticals) in collaboration with Inovio Pharmaceuticals and Washington University School of Medicine[1][2][3][4]. It belongs to the class of antineoplastics, cancer vaccines, DNA vaccines, and immunotherapies.
- Other names
- personalized neoantigen DNA vaccine GNOS-PV01gnos-pv01gnos-pv-01gnos-pv 01
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Personalized neoantigen DNA vaccine GNOS-PV01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen DNA vaccine GNOS-PV01.